Exelixis develops and sells cancer medicines, led by CABOMETYX, for physicians and their patients. It last closed at $64.63 on Nov 20, down 1.82% on the day. The next earnings report for EXEL is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Oct 2026, EXEL reported EPS of $0.85 on revenue of $658.7M, with revenue up 10.2% from a year ago. Over its last 8 reports the stock moved an average of 8.4% the session after earnings. Over the last 12 months EXEL insiders bought $1.2M of stock on the open market and sold $34.8M, according to SEC Form 4 filings.
AI Auto Pilots
Is EXEL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold EXEL.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on EXELStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
EXEL · as of the Nov 20 close · updated each morning
Moving sideways
The stock sits between its 20 and 50 day averages. It is 18% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the Pivot S1 at $63.74, and the nearest resistance the Pivot at $65.34.
Short trendNeutral
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 3.5%/day
Key levels
$73.6952 week high+14.0%
$73.69Swing high (Nov 5)+14.0%
$68.6020 day average+6.1%
$66.23Pivot R1+2.5%
$65.34Pivot+1.1%
$64.63Last close
$63.74Pivot S1−1.4%
$63.2050 day average−2.2%
$59.24100 day average−8.3%
$57.02Swing low (Oct 6)−11.8%
$52.86200 day average−18.2%
$39.7152 week low−38.6%
Indicators
RSI (14)
43.41
Middle of its range
Neutral
MACD
0.99
Below its signal line
Bearish
Stochastic
11.7
Near the bottom of its range
Oversold
ADX (14)
31.3
Trending down
Williams %R
-98.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-112.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−7.1%
Change over 10 sessions
Bearish
ATR (14)
$2.25
Typical daily range, 3.5% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Uptrend, nearing overbought
Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 6.5%/day
Key levels
$73.6952 week high+14.0%
$73.69Swing high (Nov 5)+14.0%
$68.6020 day average+6.1%
$66.23Pivot R1+2.5%
$65.34Pivot+1.1%
$64.63Last close
$63.74Pivot S1−1.4%
$63.2050 day average−2.2%
$59.24100 day average−8.3%
$57.02Swing low (Oct 6)−11.8%
$52.86200 day average−18.2%
$39.7152 week low−38.6%
Indicators
RSI (14)
63.52
Strong, overbought above 70
Neutral
MACD
4.67
Above its signal line
Bullish
Stochastic
74.4
Middle of its range
Neutral
ADX (14)
41.5
Strong uptrend
Williams %R
-39.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
104.8
Oversold below −100, overbought above 100
Overbought
Rate of change
+15.2%
Change over 10 sessions
Bullish
ATR (14)
$4.20
Typical daily range, 6.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for EXEL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how EXEL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow EXEL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for EXELHow many large options trades hit EXEL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in EXEL in the last 90 days.
From SEC Form 4 filings by EXEL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EXEL is in one of them and how their past EXEL trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Exelixis
Exelixis is a biopharmaceutical company based in Alameda, California, that develops and sells medicines for cancer. Its main product is CABOMETYX, a cabozantinib tablet used to treat several forms of kidney, liver, thyroid and neuroendocrine cancer, and it also sells COMETRIQ for medullary thyroid cancer. Its medicines are prescribed by physicians and taken by patients, with partners such as Ipsen and Takeda handling sales in markets outside the U.S. Its pipeline includes zanzalintinib, which is under review for colorectal cancer.